T 2321/13 (Hyperproliferative diseases/MAX-PLANCK-GESELLSCHAFT) of 13.09.2018
- European Case Law Identifier
- ECLI:EP:BA:2018:T232113.20180913
- Date of decision
- 13 September 2018
- Case number
- T 2321/13
- Petition for review of
- -
- Application number
- 02712879.2
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Anti HER3 antibody for diagnosis, prevention and treatment of hyperproliferative diseases
- Applicant name
- Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
- Opponent name
- F. Hoffmann-La Roche AG(CH) / Genentech, Inc.(US)
MedImmune LLC
Ablynx N.V.
Glaxo Group Limited
Merck Patent GmbH - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 84European Patent Convention R 115(2)Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 15(3)
- Keywords
- Main request - clarity (no)
Auxiliary requests 1 to 7 - admitted (no) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.